WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for the treatment of amyloidosis in a mammal in need thereof wherein the medicament is to be administered to the mammal.

2. The use of claim 1 wherein the amyloidosis is selected from Alzheimer's disease, Down's syndrome, dementia pugilistica, cognitive dysfunction syndrome, canine cognitive dysfunction, multiple system atrophy, inclusion body myositosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, Nieman-Pick disease type C, cerebral β-amyloid angiopathy, dementia associated with cortical basal degeneration, the amyloidosis of type 2 diabetes, the amyloidosis of chronic inflammation, the amyloidosis of malignancy and Familial Mediterranean Fever, the amyloidosis of multiple myeloma and B-cell dyscrasias, the amyloidosis of prion diseases, Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru, scrapie, the amyloidosis associated with carpal tunnel syndrome, senile cardiac amyloidosis, familial amyloidotic polyneuropathy, and the amyloidosis associated with endocrine tumors.

3. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for treating the formation, deposition, accumulation, or persistence of amyloid fibrils in a mammal.

4. The use of claim 3 wherein the extracts are formulated for administration by one of the routes selected from pills, tablets, caplets, soft or hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, cold and hot beverage preparations, syrups, tea bags, aerosols, suppositories, sterile injectable solutions, or sterile packaged powders.

5. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques in a mammal.

6. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for the treatment of a tauopathy in a mammal.

7. The use of claim 6 wherein the tauopathy is selected from Alzheimer's disease, frontotemporal lobar degeneration with tat inclusions (FLTD-tau), Pick's disease, progressive supranuclear palsy, corticobasal degeneration, agryophlic grain disease, prion disease, amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam (also called Lytico Bodig disease), Parkinson's disease, tangle-predominant dementia, ganglioma, ganglioglioma, gangliocytoma, meningiomatosis, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease, lipofuscinosis, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), dementia pugilistic, concussion, single or repeated blows to the head, and post-traumatic stress disorder.

8. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for treating the formation, deposition, accumulation, or persistence of tau protein containing tangles in a mammal.

9. The use of claim 8 wherein the extracts are formulated for administration by one of the routes selected from pills, tablets, caplets, soft or hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, beverage preparations, syrups, tea bags, aerosols, suppositories, sterile injectable solutions, or sterile packaged powders.

10. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for improving cognitive performance and/or slowing cognitive decline in a patient suffering from an amyloid disease wherein the medicament is to be administered to reduce formation, deposition, accumulation or persistence of beta-amyloid protein plaques or fibrils in the patient.

11. The use of claim 10 wherein the amount of *Uncaria tomentosa* extract and an oolong tea extract is between about 100-500 mg of *Uncaria tomentosa* extract and about 100-500 mg oolong tea extract.

12. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for preventing, reducing or treating tangles in the brain of a patient who has experienced single-or multiple concussions, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), post-traumatic stress disorder, brain aging, mild-cognitive impairment or Alzheimer's disease.

13. The use of claim 12 wherein the amount of the combination of *Uncaria tomentosa* extract and the oolong tea extract is between about 100-500 mg of *Uncaria tomentosa* extract and about 100-500 mg oolong tea extract.

14. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for preventing, reducing or treating plaques and tangles in the brain of an aged dog or cat.

15. The use of claim 14 wherein the amount of the *Uncaria tomentosa* extract and the oolong tea extract is between about 100-500 mg of *Uncaria tomentosa* extract and about 100-500 mg oolong tea extract.

16. Use of an effective amount of a composition comprising an *Uncaria tomentosa* extract and an oolong tea extract in the manufacture of a medicament for improving cognitive performance and/or slowing cognitive decline in an aged dog or cat suffering from brain formation, deposition, accumulation and/or persistence of plaques and tangles.

17. The use of claim 16 wherein the amount of *Uncaria tomentosa* extract and oolong tea extract is between about 100-500 mg of *Uncaria tomentosa* extract and about 100-500 mg oolong tea extract.